Evidence map›Paper›PMID 22488901›Full record

ReviewWiley interdisciplinary reviews. Nanomedicine and nanobiotechnology

Nanoformulations for molecular MRI.

Chuqiao Tu, Angelique Y Louie

Abstract readReview
In one paragraph

Review in Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Multimodality PET/MRI agents targeted to activated macrophages.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014
    Article
  4. Article
  5. Article
  6. Review
  7. The nanomedicine revolution: part 2: current and future clinical applications.P & T : a peer-reviewed journal for formulary management · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Chuqiao TuDepartment of Biomedical Engineering, University of California at Davis, Davis, CA, USA. chqtu@ucdavis.edu.
Angelique Y Louie

Funding

Multimodal mPET &mMRI Imaging InstrumentationR01EB000993 · NIBIB · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI CHERRY, SIMON R, JACOBS, RUSSELL E · 2004 to 2013
$9.2M
NIBIB NIH HHS R01 EB000993
6 · The paper itself

Abstract

Nanoscale contrast agents have shown the ability to increase the detection sensitivity of magnetic resonance imaging (MRI) by several orders of magnitude, endowing this traditionally macroscopic modality with the ability to observe unique molecular signatures. Herein, we describe three types of nanoparticulate contrast agents: iron oxide nanoparticles, gadolinium-based nanoparticles, and bio-essential manganese, cobalt, nickel, and copper ion-containing nanoformulations. Some of these agents have been approved for clinical use, but more are still under development for medical imaging. The advantages and disadvantages of each nanoformulation, in terms of intrinsic magnetism, ease of synthesis, biodistribution, etc. are discussed.

Indexed as

Diagnostic Uses of ChemicalsNanoparticlesPharmaceutical PreparationsAnimalsContrast MediaHumansMagnetic Resonance ImagingMetalsMolecular ImagingContrast MediaDiagnostic Uses of ChemicalsMetalsPharmaceutical Preparations

Identifiers

PMID22488901
PMCPMC3380179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.